Payment overview · 2025
General Payments
$507.27
22 reported records · 9 companies
Healthcare provider profile · identity verified
Ferial Abood, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALAMOGORDO, NM · NPI 1184803843
Verified facts
What the public records show
CMS Open Payments records show Ferial Abood, MD received $507.27 in general payments during 2025 across 22 reported records.
Smith+Nephew, Inc. accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $202.81 | 40.0% | 8 | 2025 |
| Reapplix Inc. | Unresolved — no canonical attribution shown | $75.29 | 14.8% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.18 | 11.1% | 3 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $52.03 | 10.3% | 3 | 2025 |
| Hydrofera LLC | Unresolved — no canonical attribution shown | $42.90 | 8.5% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $24.39 | 4.8% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $19.43 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.68 | 3.5% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $16.56 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $507.27 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| 3C Patch Kit - Box Normalized: 3c patch kit box |
Device | Reapplix Inc. | $75.29 | 3 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $74.44 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $74.28 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $56.18 | 3 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $54.09 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| LEUKOMED SORBACT Normalized: leukomed sorbact |
Device | Hydrofera LLC | $42.90 | 1 | 2025 |
Source payment records
|
|||||
| TCC-EZ Normalized: tcc ez |
Device | Integra LifeSciences Corporation | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4 Normalized: drawtex hydroconductive wound dressing with levafiber 4x4 |
Device | Urgo Medical North America, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| URGOK2 Normalized: urgok2 |
Device | Urgo Medical North America, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 454 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 423 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 53 |
| Lisinopril | Lisinopril | 325 | 47 |
| Eliquis | Apixaban | 306 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 36 |
| Sertraline Hcl | Sertraline Hcl | 222 | 34 |
| Torsemide | Torsemide | 215 | 43 |
| Spironolactone | Spironolactone | 208 | 44 |
| Mirtazapine | Mirtazapine | 203 | 36 |
| Memantine Hcl | Memantine Hcl | 173 | 22 |
| Metformin Hcl | Metformin Hcl | 161 | 23 |
| Allopurinol | Allopurinol | 155 | 24 |
| Montelukast Sodium | Montelukast Sodium | 142 | 22 |
| Potassium Chloride | Potassium Chloride | 134 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 14 |
| Donepezil Hcl | Donepezil Hcl | 113 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 109 | 18 |
| Risperidone | Risperidone | 109 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 13 |
| Trazodone Hcl | Trazodone Hcl | 101 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 14 |
| Lactulose | Lactulose | 87 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 26 |
| Losartan Potassium | Losartan Potassium | 80 | 17 |
| Divalproex Sodium | Divalproex Sodium | 76 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 75 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 14 |
| Finasteride | Finasteride | 68 | 11 |
| Baclofen | Baclofen | 65 | suppressed |
| Lamotrigine | Lamotrigine | 64 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 60 | 16 |
| Meloxicam | Meloxicam | 60 | suppressed |
| Azithromycin | Azithromycin | 59 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 12 |
| Bupropion Hcl | Bupropion Hcl | 58 | suppressed |
| Cephalexin | Cephalexin | 58 | 23 |
| Midodrine Hcl | Midodrine Hcl | 58 | suppressed |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 33 |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Rexulti | Brexpiprazole | 52 | suppressed |
| Famotidine | Famotidine | 51 | suppressed |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Enulose | Lactulose | 46 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Sucralfate | Sucralfate | 42 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 39 | 12 |
| Glipizide | Glipizide | 37 | suppressed |
| Omeprazole | Omeprazole | 37 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Amantadine | Amantadine Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 22 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Furosemide | Furosemide | 33 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 32 | 12 |
| Primidone | Primidone | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 12 |
| Carvedilol | Carvedilol | 31 | 15 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Daptomycin | Daptomycin | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 16 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 14 |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Tacrolimus | Tacrolimus | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Rifampin | Rifampin | 14 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Daptomycin-0.9% Nacl | Daptomycin In 0.9 % Sod Chlor | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $507.27 · 22 records | Smith+Nephew, Inc. | 3C Patch Kit - Box, COLLAGENASE SANTYL, DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4, GRAFIX PL, Kerecis GraftGuide, Kerecis SurgiClose, LEUKOMED SORBACT, NUZYRA, PURAPLY WOUND MATRIX, REPATHA, STRAVIX PL, TCC-EZ, URGOK2, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, XHANCE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error